Publication Topic

Frankenfeld CL, Movva N, Hooda N, Gauthier J, Reichert H, Doepker C. 2026. Analysis of National Health and Nutrition Survey (NHANES): Nutrient, food, and beverage intake of GLP-1-RA users with type 2 diabetes, 2007-2020. J Nutr 101685; doi: 10.1016/j.tjnut.2026.101685. Online ahead of print June 22. PMID: 42331063.

Perreault L, Rasouli N, Sanogo F, Movva N, Bylsma L, Suh M, Reichert H, Donsmark M, Girguis M, Frankenfeld C. A meta-analysis of persistence and adherence to glucagon-like peptide 1-based treatments among patients with type 2 diabetes in the United States. Abstract/Poster 1691-P, American Diabetes Association 2026 Scientific Sessions, New Orleans, LA, June 7, 2026.

Movva N, Girguis M, Bylsma L, Saleem N, Grasic K, Suh M, Pastula S, Frankenfeld C. 2025. Systematic literature review of glucagon-like peptide 1 (GLP-1) receptor agonist use among type 2 diabetes in the United States. PROSPERO 2025:CRD4202564618. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025646418.

Budinsky R, Urban J, Rowlands JC. 2011. An evaluation of single nucleotide polymorphisms in the human aryl hydrocarbon receptor nuclear translocator gene. Presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

Haws LC, Scott PK, Unice KM, Gough M, Harris MA, Staskal DF, Paustenbach DJ, Pavuk M. Are dioxin body burdens surrogates for other risk factors in associations between dioxin and diabetes? Dioxin 2006, Oslo, Norway, August 2006.